QuANTUM‐R, a randomised controlled phase III trial, demonstrated a modest increase in overall survival in refractory or relapsed AML treated with the FLT3‐specific inhibitor quizartinib as monotherapy, where median survival was 6.2 months in the exploratory arm compared to 4.7 months in the control arm [23]. This evidence concerns the gene FLT3 and acute myeloid leukemia.